NAVB Stock Price: Navidea Biopharmaceuticals doubles in value, not coronavirus related

  • NYSEAMERICAN: NAVB is trading at double its price on Thursday.
  • Navidea Biopharmaceuticals Inc reported encouraging results on its rheumatoid arthritis treatment. 
  • Pharma firms are in the spotlight, even if their drugs are unrelated to coronavirus.

Navidea Biopharmaceuticals, Inc, a biotechnological company that has offices in both Dublin Ireland and Ohio, in the US, is enjoying its time in the sun. NAVB reported promising results for its treatment for rheumatoid arthritis. While those are preliminary results, the second interim analysis, Phase 2B, of the company´s NAV3'31 study shows that Tc99m tilmanocept imaging can help supply robust and qualitative health controls. 

RA affects the joints and usually results in pain, swelling up, a feeling of warmth and stiffness. The autoimmune disorder affects the hands and wrists. Genetic and environmental factors are believe to be involved. It reaches between 0.5% and 1% of the population in the developed world and causes dozens of thousands of deaths per year. 

Rheumatoid Arthritis (RA) is unrelated to the coronavirus outbreak gripping the headlines and the world's attention. Broader stock markets have been rising and falling in response to hopes for a vaccine for COVID-19, and NAVB may have been under the radar. The change in its stock price may make place it in the spotlight. 

Navidea Biopharmaceuticals Inc Stock

At the time of writing, NAVB is trading at around $2.53, up 99% – or around double its value on the previous day. The shares are still below the 52-week high of $3.50 but five times more than the 52-week low.

Hong Kong is in the spotlight for investors, as China aims to tighten its grip while the US is protesting yet probably without taking action. 

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

FXStreet Trading Signals now available!

Access to real-time signals, community and guidance now!

Latest Forex News

Editors’ Picks

EUR/USD chops around amid end-of-month flows, ahead of Trump

EUR/USD is battling 1.11, close to the two-month highs amid choppy trading. Hopes for a fiscal boost in Europe and mixed satisfactory data have supported the currency pair. , Sino-American tensions are rising and investors await President Trump's China announcement.


GBP/USD advances amid US dollar weakness, shrugging off concerns

GBP/USD is trading above 1.23, edging higher amid US dollar weakness and Britain's gradual reopening. Intensifying Sino-American tensions and the Brexit impasse are ignored. 


Cryptocurrencies: $348M in matured derivatives boost the market

Futures and options contracts' expiration brings a wave of volatility to the crypto market. Ethereum takes advantage and attacks resistances in the market dominance chart, Bitcoin goes back. Ripple disappoints despite regaining the third place in market capitalization.

Read more

Canada's economy falls by 8.2% annualized in Q1, better than expected, USD/CAD shakes

The Canadian economy squeezed by an annualized rate of 8.2% in the first quarter of 2020, better than -10% expected. Quarterly, Gross Domestic Product (GDP) squeezed by 2.1%. Most of the downfall occurred in March, with a drop of 7.2%, better than 8.5% projected. 

Read more

WTI drops 4% and eyes $32 mark amid risk-off, weakening demand

The selling pressure around WTI (July futures on Nymex) accelerates following the break below the 33 level, as bears now target the 32 support zone heading into the key US macro data and US President Donald Trump’s response to the Hong Kong issue.

Oil News